Connecting genomic alterations to cancer biology with proteomics: The NCI clinical proteomic tumor analysis consortium

Cancer Discovery

Volumn 3, Issue 10, 2013, Pages 1108-1112

  Ellis, Matthew J ^a   Gillette, Michael ^b   Carr, Steven A ^b   Paulovich, Amanda G ^c   Smith, Richard D ^d   Rodland, Karin K ^d   Townsend, R Reid ^a   Kinsinger, Christopher ^e   Mesri, Mehdi ^e   Rodriguez, Henry ^e   Liebler, Daniel C ^f  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d PACIFIC NORTHWEST NATIONAL LABORATORY   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

^f VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; MICRORNA; PHOSPHOPROTEIN; PROTEOME; TUMOR PROTEIN;

ARTICLE; BIOINFORMATICS; BREAST CANCER; CANCER RESEARCH; COLON CANCER; COPY NUMBER VARIATION; GENE EXPRESSION; GENE MUTATION; GENETIC VARIABILITY; GENOME ANALYSIS; HUMAN; MOLECULAR GENETICS; MUTATION RATE; OVARY CANCER; PHENOTYPE; PROTEIN DEFECT; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEOMICS; SEQUENCE ALIGNMENT; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

BREAST NEOPLASMS; COLONIC NEOPLASMS; COMPUTATIONAL BIOLOGY; FEMALE; GENOME, HUMAN; GENOMICS; GENOTYPE; HUMANS; MOLECULAR SEQUENCE ANNOTATION; MUTATION; NATIONAL CANCER INSTITUTE (U.S.); NATIONAL HUMAN GENOME RESEARCH INSTITUTE (U.S.); NEOPLASMS; OVARIAN NEOPLASMS; PHENOTYPE; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 84885647278     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-13-0219     Document Type: Article

References (20)

1. Ellis MJ, Perou CM. The genomic landscape of breast cancer as a therapeutic roadmap. Cancer Discov 2013; 3: 27-34.
2. Goldstein TC, Paull EO, Ellis MJ, Stuart JM. Molecular pathways: extracting medical knowledge from high-throughput genomic data. Clin Cancer Res 2013; 19: 3114-20.
3. Picotti P, Aebersold R. Selected reaction monitoring-based proteomics: workfl ows, potential, pitfalls and future directions. Nat Methods 2012; 9: 555-66.
4. Gillette MA, Carr SA. Quantitative analysis of peptides and proteins in biomedicine by targeted mass spectrometry. Nat Methods 2013; 10: 28-34.
5. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490: 61-70.
6. Rudnick PA, Clauser KR, Kilpatrick LE, Tchekhovskoi DV, Neta P, Blonder N, et al. Performance metrics for liquid chromatographytandem mass spectrometry systems in proteomics analyses. Mol Cell Proteomics 2010; 9: 225-41.
7. Addona TA, Abbatiello SE, Schilling B, Skates SJ, Mani DR, Bunk DM, et al. Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat Biotechnol 2009; 27: 633-41.
8. MacLean B, Tomazela DM, Shulman N, Chambers M, Finney GL, Frewen B, et al. Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics 2010; 26: 966-8.
9. Mertins P, Udeshi ND, Clauser KR, Mani DR, Patel J, Ong SE, et al. iTRAQ labeling is superior to mTRAQ for quantitative global proteomics and phosphoproteomics. Mol Cell Proteomics 2012; 11: M111 014423.
10. Liu H, Sadygov RG, Yates JR. A model for random sampling and estimation of relative protein abundance in shotgun proteomics. Anal Chem 2004; 76: 4193-201.
11. Michalski A, Damoc E, Lange O, Denisov E, Nolting D, Muller M, et al. Ultra high resolution linear ion trap Orbitrap mass spectrometer (Orbitrap Elite) facilitates top down LC MS/MS and versatile peptide fragmentation modes. Mol Cell Proteomics 2012; 11: O111 013698.
12. Gallien S, Duriez E, Crone C, Kellmann M, Moehring T, Domon B. Targeted proteomic quantification on quadrupole-orbitrap mass spectrometer. Mol Cell Proteomics 2012; 11: 1709-23.
13. Wolf-Yadlin A, Hautaniemi S, Lauffenburger DA, White FM. Multiple reaction monitoring for robust quantitative proteomic analysis of cellular signaling networks. Proc Natl Acad Sci U S A 2007; 104: 5860-5.
14. Zhang G, Fang B, Liu RZ, Lin H, Kinose F, Bai Y, et al. Mass spectrometry mapping of epidermal growth factor receptor phosphorylation related to oncogenic mutations and tyrosine kinase inhibitor sensitivity. J Proteome Res 2011; 10: 305-19.
15. Bai Y, Li J, Fang B, Edwards A, Zhang G, Bui M, et al. Phosphoproteomics identifies driver tyrosine kinases in sarcoma cell lines and tumors. Cancer Res 2012; 72: 2501-11.
16. Halvey PJ, Ferrone CR, Liebler DC. GeLC-MRM quantitation of mutant KRAS oncoprotein in complex biological samples. J Proteome Res 2012; 11: 3908-13.
17. Chen Y, Gruidl M, Remily-Wood E, Liu RZ, Eschrich S, Lloyd M, et al. Quantification of beta-catenin signaling components in colon cancer cell lines, tissue sections, and microdissected tumor cells using reaction monitoring mass spectrometry. J Proteome Res 2010; 9: 4215-27.
18. Razavi M, Frick LE, LaMarr WA, Pope ME, Miller CA, Anderson NL, et al. High-throughput SISCAPA quantitation of peptides from human plasma digests by ultrafast, liquid chromatography-free mass spectrometry. J Proteome Res 2012; 11: 5642-9.
19. Shi T, Fillmore TL, Sun X, Zhao R, Schepmoes AA, Hossain M, et al. Antibody-free, targeted mass-spectrometric approach for quantification of proteins at low picogram per milliliter levels in human plasma/serum. Proc Natl Acad Sci U S A 2012; 109: 15395-400.
20. Liu Q, Halvey PJ, Shyr Y, Slebos RJ, Liebler DC, Zhang B. Integrative omics analysis reveals the importance and scope of translational repression in microRNA-mediated regulation. Mol Cell Proteomics 2013; 12: 1900-11.